A detailed history of Bank Of America Corp transactions in Dyne Therapeutics, Inc. stock. As of the latest transaction made, Bank Of America Corp holds 176,774 shares of DYN stock, worth $5.27 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
176,774
Previous 152,632 15.82%
Holding current value
$5.27 Million
Previous $4.33 Million 43.96%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$23.65 - $35.63 $570,958 - $860,179
24,142 Added 15.82%
176,774 $6.24 Million
Q1 2024

May 15, 2024

BUY
$13.06 - $29.18 $1.46 Million - $3.26 Million
111,850 Added 274.26%
152,632 $4.33 Million
Q4 2023

Feb 14, 2024

SELL
$6.62 - $13.64 $337,289 - $694,958
-50,950 Reduced 55.54%
40,782 $542,000
Q2 2023

Aug 14, 2023

BUY
$8.53 - $14.28 $168,561 - $282,187
19,761 Added 27.46%
91,732 $1.03 Million
Q1 2023

May 12, 2023

BUY
$10.88 - $15.0 $393,910 - $543,075
36,205 Added 101.23%
71,971 $829,000
Q4 2022

Feb 10, 2023

SELL
$9.37 - $13.8 $141,046 - $207,731
-15,053 Reduced 29.62%
35,766 $414,000
Q3 2022

Nov 14, 2022

BUY
$7.2 - $15.17 $162,072 - $341,476
22,510 Added 79.52%
50,819 $645,000
Q2 2022

Aug 12, 2022

SELL
$4.36 - $10.5 $19,458 - $46,861
-4,463 Reduced 13.62%
28,309 $194,000
Q1 2022

May 16, 2022

SELL
$6.52 - $12.27 $203,730 - $383,400
-31,247 Reduced 48.81%
32,772 $316,000
Q4 2021

Feb 08, 2022

BUY
$11.89 - $16.07 $603,013 - $815,006
50,716 Added 381.24%
64,019 $762,000
Q3 2021

Nov 15, 2021

SELL
$15.6 - $21.46 $5,226 - $7,189
-335 Reduced 2.46%
13,303 $216,000
Q2 2021

Sep 13, 2021

BUY
$15.94 - $22.33 $217,389 - $304,536
13,638 New
13,638 $287,000

Others Institutions Holding DYN

About Dyne Therapeutics, Inc.


  • Ticker DYN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 51,765,400
  • Market Cap $1.54B
  • Description
  • Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and...
More about DYN
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.